1324-1325 / 2063
CHHiP-trial
•
74 Gy / 2 Gy (37#) vs 60 Gy / 3 Gy (20#) vs 57 Gy / 3 Gy (19#)
• 3152 analysable patients
• 73% Intermediate risk; 15% Low risk; 12% High risk (NCCN)
• 97% Androgen deprivation (3-6 months)
• IMRT
• Non-inferior design (bNED or cNED -free survival
±
5% at 5
years)
Dearnaley et al. Lancet Oncol.
2016